Cytokinetics Inc vs ProShares Ultra QQQ ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while ProShares Ultra QQQ ETF trades at $92.22. Which is the better fit depends on your goals.
| CYTK | QLD | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $100.53 |
52-Week Low | $34.31 | $57.16 |
Enterprise Value | $10.74B | — |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
QLD, the ProShares Ultra QQQ ETF, trades at $92.32, up 0.75% today, reflecting a bullish technical stance with moving averages signaling strength. The fund offers 2x daily leveraged exposure to the Nasdaq-100 index, having delivered over 10,000% total return since inception. Recent institutional buying includes 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026 (SEC Form 13F filing, August 6, 2026).
Outlook remains tied to tech sector performance, with AI optimism and easing geopolitical tensions cited as tailwinds (Zacks Investment Research, May 29, 2026). Key risks include leveraged ETF decay and volatility, evidenced by a 63.80% historical maximum drawdown. The neutral oscillator reading suggests near-term consolidation may precede further moves.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →